|
1
|
Cazzaniga ME, Cortesi L, Ferzi A,
Scaltriti L, Cicchiello F, Ciccarese M, Torre SD, Villa F, Giordano
M, Verusio C, et al: Metronomic chemotherapy in triple-negative
metastatic breast cancer: The future is now? Int J Breast Cancer.
2017:16830602017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chalakur-Ramireddy NKR and Pakala SB:
Combined drug therapeutic strategies for the effective treatment of
Triple Negative Breast Cancer. Biosci Rep. 38:pii: BSR20171357.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omarini C, Guaitoli G, Pipitone S,
Moscetti L, Cortesi L, Cascinu S and Piacentini F: Neoadjuvant
treatments in triple-negative breast cancer patients: Where we are
now and where we are going. Cancer Manag Res. 10:91–103. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rabanal C, Ruiz R, Neciosup S and Gomez H:
Metronomic chemotherapy for non-metastatic triple negative breast
cancer: Selection is the key. World J Clin Oncol. 8:437–446. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reaz S, Tamkus D and Andrechek ER: Using
gene expression data to direct breast cancer therapy: evidence from
a preclinical trial. J Mol Med (Berl). 96:111–117. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sulaiman A and Wang L: Bridging the
divide: Preclinical research discrepancies between triple-negative
breast cancer cell lines and patient tumors. Oncotarget.
8:113269–113281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Horton JK, Jagsi R, Woodward WA and Ho A:
Breast cancer biology: Clinical implications for breast radiation
therapy. Int J Radiat Oncol Biol Phys. 100:23–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartsch R and Bergen E: ASCO 2017:
Highlights in breast cancer. Memo. 10:228–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pal SK, Childs BH and Pegram M: Triple
negative breast cancer: Unmet medical needs. Breast Cancer Res
Treat. 125:627–636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu
GY, Wu J, Shen KW, Han QX, Shen ZZ and Shao ZM: Clinicopathological
features of the triple-negative tumors in Chinese breast cancer
patients. Breast Cancer Res Treat. 115:325–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paez-Ribes M, Allen E, Hudock J, Takeda T,
Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason
GA, Christensen JG and Kerbel RS: Accelerated metastasis after
short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carbone C, Moccia T, Zhu C, Paradiso G,
Budillon A, Chiao PJ, Abbruzzese JL and Melisi D: Anti-VEGF
treatment-resistant pancreatic cancers secrete proinflammatory
factors that contribute to malignant progression by inducing an EMT
cell phenotype. Clin Cancer Res. 17:5822–5832. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shirakawa K, Wakasugi H, Heike Y, Watanabe
I, Yamada S, Saito K and Konishi F: Vasculogenic mimicry and
pseudo-comedo formation in breast cancer. Int J Cancer. 99:821–828.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang JY, Sun T, Zhao XL, Zhang SW, Zhang
DF, Gu Q, Wang XH, Zhao N, Qie S and Sun BC: Functional
significance of VEGF-a in human ovarian carcinoma: Role in
vasculogenic mimicry. Cancer Biol Ther. 7:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K,
Pang JC, Ng HK and Chen ZP: Clinical significance of vasculogenic
mimicry in human gliomas. J Neurooncol. 105:173–179. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao
S, Ni C, Wang X, Liu Y and Zhang L: Role and mechanism of
vasculogenic mimicry in gastrointestinal stromal tumors. Hum
Pathol. 39:444–451. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW,
Che N, Wang XH, Du J, Liu YX and Sun BC: Expression and functional
significance of Twist1 in hepatocellular carcinoma: Its role in
vasculogenic mimicry. Hepatology. 51:545–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li M, Gu Y, Zhang Z, Zhang S, Zhang D,
Saleem AF, Zhao X and Sun B: Vasculogenic mimicry: A new prognostic
sign of gastric adenocarcinoma. Pathol Oncol Res. 16:259–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gong W, Sun B, Zhao X, Zhang D, Sun J, Liu
T, Gu Q, Dong X, Liu F, Wang Y, et al: Nodal signaling promotes
vasculogenic mimicry formation in breast cancer via the Smad2/3
pathway. Oncotarget. 7:70152–70167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zeng YE, Yao XH, Yan ZP, Liu JX and Liu
XH: Potential signaling pathway involved in
sphingosine-1-phosphate-induced epithelial-mesenchymal transition
in cancer. Oncol Lett. 12:379–382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeng Y, Yao X, Chen L, Yan Z, Liu J, Zhang
Y, Feng T, Wu J and Liu X: Sphingosine-1-phosphate induced
epithelial-mesenchymal transition of hepatocellular carcinoma via
an MMP-7/syndecan-1/TGF-β autocrine loop. Oncotarget.
7:63324–63337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Z, Sun B, Qi L, Li H, Gao J and Leng
X: Zinc finger E-box binding homeobox 1 promotes vasculogenic
mimicry in colorectal cancer through induction of
epithelial-to-mesenchymal transition. Cancer Sci. 103:813–820.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Francescone R, Scully S, Bentley B, Yan W,
Taylor SL, Oh D, Moral L and Shao R: Glioblastoma-derived tumor
cells induce vasculogenic mimicry through Flk-1 protein activation.
J Biol Chem. 287:24821–24831. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Song S, Xu Y, Zhao J and Liu H:
Knockdown of ZEB1 suppresses the formation of vasculogenic mimicry
in breast cancer cell line MDA-MB-231 through downregulation of
Flk-1. Minerva Med. 108:191–193. 2017.PubMed/NCBI
|
|
28
|
Wang H, Lin H, Pan J, Mo C, Zhang F, Huang
B, Wang Z, Chen X, Zhuang J, Wang D and Qiu S: Vasculogenic mimicry
in prostate cancer: The roles of EphA2 and PI3K. J Cancer.
7:1114–1124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Timoshenko AV, Kaltner H, Andrè S, Gabius
HJ and Lala PK: Differential stimulation of VEGF-C production by
adhesion/growth-regulatory galectins and plant lectins in human
breast cancer cells. Anticancer Res. 30:4829–4833. 2010.PubMed/NCBI
|
|
30
|
Yao L, Zhang D, Zhao X, Sun B, Liu Y, Gu
Q, Zhang Y, Zhao X, Che N, Zheng Y, et al: Dickkopf-1-promoted
vasculogenic mimicry in non-small cell lung cancer is associated
with EMT and development of a cancer stem-like cell phenotype. J
Cell Mol Med. 20:1673–1685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li S, Zhang HY, Du ZX, Li C, An MX, Zong
ZH, Liu BQ and Wang HQ: Induction of epithelial-mesenchymal
transition (EMT) by Beclin 1 knockdown via posttranscriptional
upregulation of ZEB1 in thyroid cancer cells. Oncotarget.
7:70364–70377. 2016.PubMed/NCBI
|
|
32
|
Gao HX, Yan L, Li C, Zhao LM and Liu W:
miR-200c regulates crizotinib-resistant ALK-positive lung cancer
cells by reversing epithelial-mesenchymal transition via targeting
ZEB1. Mol Med Rep. 14:4135–4143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bussolati B, Grange C, Sapino A and
Camussi G: Endothelial cell differentiation of human breast tumour
stem/progenitor cells. J Cell Mol Med. 13:309–319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chroscinski D, Sampey D and Maherali N:
Reproducibility Project; Cancer Biology: Registered report: Tumour
vascularization via endothelial differentiation of glioblastoma
stem-like cells. Elife. 4:2015.doi: 10.7554/eLife.04363. View Article : Google Scholar
|
|
35
|
Ricci-Vitiani L, Pallini R, Biffoni M,
Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G,
Larocca LM and De Maria R: Tumour vascularization via endothelial
differentiation of glioblastoma stem-like cells. Nature.
468:824–828. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan YL, Zheng M, Tang YL and Liang XH: A
new perspective of vasculogenic mimicry: EMT and cancer stem cells
(Review). Oncol Lett. 6:1174–1180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop-a motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Radisky DC: miR-200c at the nexus of
epithelial-mesenchymal transition, resistance to apoptosis, and the
breast cancer stem cell phenotype. Breast Cancer Res. 13:1102011.
View Article : Google Scholar : PubMed/NCBI
|
